IL240894B - Combinations of decitabine derivatives and other active substances, kits and preparations containing them and their uses - Google Patents

Combinations of decitabine derivatives and other active substances, kits and preparations containing them and their uses

Info

Publication number
IL240894B
IL240894B IL240894A IL24089415A IL240894B IL 240894 B IL240894 B IL 240894B IL 240894 A IL240894 A IL 240894A IL 24089415 A IL24089415 A IL 24089415A IL 240894 B IL240894 B IL 240894B
Authority
IL
Israel
Prior art keywords
decitabine
kits
derivatives
compositions
combinations
Prior art date
Application number
IL240894A
Other languages
English (en)
Hebrew (he)
Other versions
IL240894A0 (en
Original Assignee
Astex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astex Pharmaceuticals Inc filed Critical Astex Pharmaceuticals Inc
Publication of IL240894A0 publication Critical patent/IL240894A0/en
Publication of IL240894B publication Critical patent/IL240894B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001189—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL240894A 2013-03-01 2015-08-27 Combinations of decitabine derivatives and other active substances, kits and preparations containing them and their uses IL240894B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361771525P 2013-03-01 2013-03-01
US201361887165P 2013-10-04 2013-10-04
PCT/US2014/019137 WO2014134355A1 (en) 2013-03-01 2014-02-27 Drug combinations

Publications (2)

Publication Number Publication Date
IL240894A0 IL240894A0 (en) 2015-10-29
IL240894B true IL240894B (en) 2020-10-29

Family

ID=50288308

Family Applications (2)

Application Number Title Priority Date Filing Date
IL240894A IL240894B (en) 2013-03-01 2015-08-27 Combinations of decitabine derivatives and other active substances, kits and preparations containing them and their uses
IL277385A IL277385A (en) 2013-03-01 2020-09-15 Combinations of decitabine derivatives and other active substances, kits and preparations containing them and their uses

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL277385A IL277385A (en) 2013-03-01 2020-09-15 Combinations of decitabine derivatives and other active substances, kits and preparations containing them and their uses

Country Status (24)

Country Link
US (2) US20160015805A1 (OSRAM)
EP (2) EP3563836A1 (OSRAM)
JP (2) JP6514647B2 (OSRAM)
KR (1) KR20150125963A (OSRAM)
CN (2) CN105025884B (OSRAM)
AU (1) AU2014223348B2 (OSRAM)
CA (1) CA2902433A1 (OSRAM)
CY (1) CY1122554T1 (OSRAM)
DK (1) DK2961388T3 (OSRAM)
ES (1) ES2734023T3 (OSRAM)
HR (1) HRP20191171T1 (OSRAM)
HU (1) HUE044430T2 (OSRAM)
IL (2) IL240894B (OSRAM)
LT (1) LT2961388T (OSRAM)
MX (2) MX366967B (OSRAM)
PH (2) PH12015501905A1 (OSRAM)
PL (1) PL2961388T3 (OSRAM)
PT (1) PT2961388T (OSRAM)
RU (2) RU2019138702A (OSRAM)
SA (1) SA515360959B1 (OSRAM)
SG (2) SG11201506727RA (OSRAM)
SI (1) SI2961388T1 (OSRAM)
WO (1) WO2014134355A1 (OSRAM)
ZA (2) ZA201506150B (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
JP6038921B2 (ja) 2011-08-30 2016-12-07 アステックス ファーマシューティカルズ インコーポレイテッド デシタビン誘導体製剤
KR102248804B1 (ko) 2014-03-12 2021-05-11 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
PL3142751T3 (pl) 2014-05-13 2019-12-31 Medimmune Limited Przeciwciała anty-b7-h1 i anty-ctla-4 do leczenia niedrobnokomórkowego nowotworu płuca
CA2955177A1 (en) * 2014-07-15 2016-01-21 The Johns Hopkins University Suppression of myeloid derived suppressor cells and immune checkpoint blockade
ES2882827T3 (es) 2014-10-07 2021-12-02 Cytlimic Inc Péptido inductor de inmunidad derivado de HSP70
WO2016061231A1 (en) * 2014-10-14 2016-04-21 Deciphera Pharmaceuticals, Llc Inhibition of tumor cell interactions with the microenvironment resulting in a reduction in tumor growth and disease progression
US10525035B2 (en) * 2014-12-18 2020-01-07 Lankenau Institute For Medical Research Methods and compositions for the treatment of retinopathy and other ocular diseases
MA41463A (fr) 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
CN107428815B (zh) 2015-03-09 2021-07-09 Cytlimic公司 源于gpc3的肽、使用其的用于治疗或预防癌症的医药组合物、免疫诱导剂、及抗原呈递细胞的制造方法
DK3281641T3 (da) 2015-04-07 2021-01-18 Cytlimic Inc Adjuvans til cancervacciner
MX2018000016A (es) * 2015-07-02 2019-01-31 Otsuka Pharma Co Ltd Composiciones farmaceuticas liofilizadas.
RU2759728C2 (ru) 2016-10-11 2021-11-17 Ситлимик Инк. Лекарственное средство
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704966D0 (en) * 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
MX2020001233A (es) 2017-08-03 2020-07-20 Otsuka Pharma Co Ltd Compuesto farmaceutico y metodos de purificacion del mismo.
EP3727374A4 (en) * 2017-12-21 2021-11-10 Merck Patent GmbH COMBINATION OF AN ANTI-PD-L1 ANTIBODY AND AN IDO1 INHIBITOR FOR THE TREATMENT OF CANCER
CN108948203B (zh) * 2018-08-09 2019-06-04 南京鼓楼医院 抗pd-1单克隆抗体及其制备方法和应用
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
PH12022552820A1 (en) * 2020-04-24 2024-03-25 Genexine Inc Method for treating cervical cancer

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009817A1 (en) 1992-11-04 1994-05-11 City Of Hope Novel antibody construct
DE69943359D1 (de) 1998-02-05 2011-05-26 Glaxosmithkline Biolog Sa Tumorassoziierte Antigenderivate der Mage-Familie, zur Herstellung von Fusionsproteinen mit T-Helper Epitope und Zusammensetzungen zur Impfung
ES2706547T3 (es) 1998-12-23 2019-03-29 Pfizer Anticuerpos monoclonales humanos para CTLA-4
WO2000062800A2 (en) * 1999-04-19 2000-10-26 Smithkline Beecham Biologicals Sa Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
GB9908885D0 (en) * 1999-04-19 1999-06-16 Smithkline Beecham Biolog Vccine
WO2001014424A2 (en) 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
US6613753B2 (en) * 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
US20030148973A1 (en) 2001-05-23 2003-08-07 Peter Emtage MAGE-A1 peptides for treating or preventing cancer
EP1551225A4 (en) * 2002-06-10 2011-05-25 Avax Technologies Inc KRYOKONSERVATION OF HAPEN-MODIFIED TUMOR CELLS
WO2005033278A2 (en) 2003-09-30 2005-04-14 Ludwig Institute For Cancer Research In vivo efficacy of ny-eso-1 plus iscom
DE602005012686D1 (de) * 2004-05-26 2009-03-26 Biovaxim Ltd Zusammensetzungen aus demethylierenden mitteln als verstärker der immuntherapie zur behanldung von cngen und behandlungsverfahren dafür
KR20070067702A (ko) 2004-11-04 2007-06-28 화이자 프로덕츠 인크. 유방암을 치료하기 위한 ｃｔｌａ-4 항체와 아로마타제억제제 병용 요법
US20060159694A1 (en) 2004-12-29 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in compositions for various types of cancers
US20060240047A1 (en) * 2005-01-14 2006-10-26 Avax Technologies, Inc. Method for producing a vaccine for the treatment of cancer
EP1896582A4 (en) 2005-05-09 2009-04-08 Ono Pharmaceutical Co HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED CELL DEATH 1 (PD-1) AND METHOD FOR CREATING TREATMENT WITH ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
WO2007028047A2 (en) * 2005-09-01 2007-03-08 Celgene Corporation Immunological uses of immunodulatory compounds for vaccine and anti-infections disease therapy
US7700567B2 (en) * 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
SG177564A1 (en) * 2009-07-06 2012-02-28 Ontorii Inc Novel nucleic acid prodrugs and methods of use thereof
DK2769737T3 (en) * 2009-07-20 2017-07-24 Bristol Myers Squibb Co COMBINATION OF ANTI-CTLA4 ANTIBODY WITH ETOPOSIDE FOR SYNERGISTIC TREATMENT OF PROLIFERATIVE DISEASES
JP2013506697A (ja) * 2009-10-06 2013-02-28 アンジオケム インコーポレーテッド 治療薬を輸送するための組成物と方法
GB201006096D0 (en) * 2010-04-13 2010-05-26 Alligator Bioscience Ab Novel compositions and uses thereof
JP6121904B2 (ja) 2010-09-08 2017-04-26 ハロザイム インコーポレイテッド 条件的活性治療用タンパク質を評価および同定する、または発展させる方法
SG194099A1 (en) * 2011-04-15 2013-11-29 Compugen Ltd Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
JP6038921B2 (ja) * 2011-08-30 2016-12-07 アステックス ファーマシューティカルズ インコーポレイテッド デシタビン誘導体製剤
EP2958571B1 (en) * 2013-02-21 2024-04-10 Michele Maio Dna hypomethylating agents for cancer therapy

Also Published As

Publication number Publication date
RU2015141628A (ru) 2017-04-06
SA515360959B1 (ar) 2019-04-03
RU2708246C2 (ru) 2019-12-05
PH12015501905A1 (en) 2016-01-11
IL240894A0 (en) 2015-10-29
ZA201506150B (en) 2019-11-27
LT2961388T (lt) 2019-08-26
CY1122554T1 (el) 2021-01-27
ZA201905426B (en) 2022-07-27
SG10201707135RA (en) 2017-10-30
CN105025884B (zh) 2019-08-20
HK1219663A1 (en) 2017-04-13
NZ711757A (en) 2020-09-25
PH12019550222A1 (en) 2021-10-04
NZ750690A (en) 2020-09-25
AU2014223348B2 (en) 2018-12-13
MX2015011147A (es) 2016-04-28
DK2961388T3 (da) 2019-07-08
AU2014223348A1 (en) 2015-09-03
EP2961388B1 (en) 2019-04-24
EP3563836A1 (en) 2019-11-06
CN105025884A (zh) 2015-11-04
US20160015805A1 (en) 2016-01-21
RU2015141628A3 (OSRAM) 2018-03-07
IL277385A (en) 2020-11-30
US20200009247A1 (en) 2020-01-09
CN110448566A (zh) 2019-11-15
WO2014134355A1 (en) 2014-09-04
MX2019008822A (es) 2019-09-26
RU2019138702A (ru) 2020-01-27
HUE044430T2 (hu) 2019-10-28
SI2961388T1 (sl) 2019-10-30
JP6514647B2 (ja) 2019-05-15
JP2019142911A (ja) 2019-08-29
KR20150125963A (ko) 2015-11-10
SG11201506727RA (en) 2015-09-29
PL2961388T3 (pl) 2019-10-31
HRP20191171T1 (hr) 2019-10-04
MX366967B (es) 2019-07-31
EP2961388A1 (en) 2016-01-06
PT2961388T (pt) 2019-07-11
ES2734023T3 (es) 2019-12-03
JP2016510030A (ja) 2016-04-04
CA2902433A1 (en) 2014-09-04

Similar Documents

Publication Publication Date Title
IL277385A (en) Combinations of decitabine derivatives and other active substances, kits and preparations containing them and their uses
HUE048666T2 (hu) Mezõgazdasági endofita-növény kompozíciók és alkalmazási eljárások
IL243752B (en) Multispecific antibodies, preparations containing them and their uses
IL240196B (en) Amide compounds, preparations containing them and their uses
EP3043824A4 (en) Modified therapeutic agents and compositions thereof
PT2755473T (pt) Composições parasiticidas compreendendo um agente ativo de isoxazolina, métodos e suas utilizações
IL265876A (en) Preparations that include 15-ohepa and methods of using them
EP3030266A4 (en) Topical compositions and methods of using the same
IL234014A0 (en) Cycloalkane derivatives, preparations containing them and their uses
CA3284288A1 (en) Topical compositions and methods of using the same
IL241355B (en) Pyrazole-amide compounds, preparations containing them and their uses
ZA201509262B (en) Tuberculosis compositions and methods of using the same
IL239840A0 (en) Polymyxins, preparations, methods of preparation and methods of use
IL241359A0 (en) Converted indole-5-ol derivatives, preparations containing them and their uses
IL276126B (en) Preparations containing l-4-chloroquinonerine and their uses
EP2976091C0 (de) Antioxidativ wirksame zusammensetzung und deren verwendung
PL2961822T3 (pl) Preparaty, ich zastosowanie jako środków do zmywania naczyń lub do wytwarzania środków do zmywania naczyń i ich wytwarzanie
GB2533234B (en) Ocular composition and kits thereof
PL2989192T3 (pl) Preparaty, ich zastosowanie jako środków do zmywania naczyń lub do wytwarzania środków do zmywania naczyń i ich wytwarzanie
IL233682A0 (en) Modified phenylazole derivatives, preparations containing them and their uses
EP2967055A4 (en) BIOCIDAL COMPOSITIONS, METHODS OF MAKING, AND METHODS OF USE
EP2995294A4 (en) Bathing agent composition
BR112016008035A2 (pt) composição, uso da composição
AU2013902944A0 (en) Detergent compositions and their use
GB201300628D0 (en) Compositions comprising 15-OHEPA and methods of using the same

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed